Home » Blog » Centre Proposes Stricter Rules for Antimicrobial Drugs to Tackle AMR

Centre Proposes Stricter Rules for Antimicrobial Drugs to Tackle AMR

New Delhi, Nov 19: In a significant move to strengthen India’s fight against antimicrobial resistance (AMR), the Union Ministry of Health and Family Welfare has proposed bringing antimicrobial products under tighter central regulatory control by amending the New Drugs and Clinical Trials Rules, 2019.

Centre Proposes Stricter Rules for Antimicrobial Drugs to Tackle AMR

 Representational Image 

The proposed amendment, notified through draft Gazette Notification G.S.R. 983 (E) dated November 6, 2026, seeks to include ‘antimicrobials’ within the definition of ‘New Drug’ under Rule 2(1)(w)(v) of the existing rules.

The move aims to address regulatory gaps in the manufacturing and licensing of antimicrobial products and ensure that medicines entering the market meet appropriate standards of quality, safety and efficacy.

Stronger checks on antimicrobial manufacturing

The Ministry’s proposal comes amid concerns over the grant of manufacturing licences for antimicrobial products without sufficient regulatory scrutiny. In particular, the absence of essential assessments, including bioavailability and bioequivalence studies and stability studies, may compromise the quality and effectiveness of these medicines.

Substandard or ineffective antimicrobial products can undermine treatment outcomes and contribute to the emergence and spread of antimicrobial resistance, posing a serious threat to public health and patient safety.

Under the proposed framework, manufacturers would need to obtain prior permission from the Central Licensing Authority (CLA) before approaching the respective State Licensing Authority (SLA) for a manufacturing licence.

This change is expected to strengthen regulatory coordination between central and state authorities while ensuring more rigorous evaluation of antimicrobial products before they enter the market.

One Health approach to tackling AMR

Antimicrobial resistance has emerged as a major global public health challenge, requiring coordinated efforts across human health, animal health and the environment.

India’s proposed regulatory intervention also aligns with the broader international commitment to addressing AMR through the One Health approach. The G20 New Delhi Leaders’ Declaration had highlighted the importance of collective action to tackle this growing challenge.

By strengthening oversight of antimicrobial manufacturing, the proposed amendment seeks to support responsible access to quality medicines and reinforce efforts to contain the spread of drug-resistant infections.

Leave a Reply

Your email address will not be published. Required fields are marked *